Oslo, 5 July 2024: Reference is made to the stock exchange announcements by
Circio Holding ASA (the "Company") on 24 June 2024, regarding the commencement
of the subscription period for the rights issue (the "Rights Issue") and the
receipt of subscription rights in the Rights Issue by certain primary insiders
and close associates.

Damian Marron, Chairman of the board of directors, has on 5 July 2024 exercised
3,604 subscription rights, thus entitling him to be allocated 3,604 offer shares
in the Rights Issue. In addition, Damian Marron has subscribed for 140,000 offer
shares without subscription rights, thereby subscribing for a total of 143,604
offer shares at the subscription price in the Rights Issue, i.e., NOK 2.50 per
offer share, and to be allocated a corresponding number in warrants without
additional consideration, subject to allocation by the board of directors and
the completion of the Rights Issue.

Please see the attached notifications of trade for information regarding the
subscription rights exercised by primary insiders in the Rights Issue.

This information is subject to the disclosure requirements pursuant to article
19 of the EU Market Abuse Regulation and section 5-12 of the Norwegian
Securities Trading Act.

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@circio.com

Lubor Gaal, CFO
Phone: +34 683343811
Email: lubor.gaal@circio.com

About Circio

Building next generation RNA therapeutics

Circio Holding ASA is a biotechnology company developing novel circular RNA gene
therapies and immunotherapy medicines.

Circio has established a unique circular RNA (circRNA) platform for genetic
medicine. The proprietary circVec technology is based on a modular genetic
cassette design for efficient biogenesis of multifunctional circRNA from DNA and
viral vectors, which can be deployed in multiple disease settings. The circVec
platform has demonstrated enhanced and more durable protein expression than
classic mRNA vector systems, and has the potential to become the new gold
-standard for DNA and virus-based therapeutics in the future. The circRNA R&D
activities are being conducted by the wholly owned subsidiary Circio AB based at
the Karolinska Institute in Stockholm, Sweden.

In addition, Circio is developing a cancer vaccine, TG01, targeting KRAS driver
mutations. TG01 is currently being tested in three clinical trials: RAS-mutated
pancreatic cancer and lung and non-resectable pancreatic cancer in US, and
multiple myeloma in Norway. These studies are being run through academic
collaborative networks, supported by prestigious research grants from Innovation
Norway and the Norwegian Research Council, creating read-outs and future
optionality for the program at low cost to Circio.